ArticleBMC neurology2026
Guillain-Barré syndrome and its variants during COVID-19 pandemic: a retrospective study in Iran.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuillain-Barre syndrome (GBS) is a rare neurologic disorder with potential associations with viral triggers. This study aimed to investigate the incidence of GBS and its variants during COVID-19 pandemic in patients admitted to Kerman Shafa Hospital within 2020-2023.
methodsThis was retrospective cross-sectional analysis of GBS cases reported during the COVID-19 pandemic in Shafa Hospital -Kerman during 2020-2023. to explore the incidence rate of GBS and, the association between demographic variables, the history of COVID-19 infection and vaccination within one month of GBS diagnosis, and the clinical outcomes. Data were analyzed using the SPSS 26 software.
resultsA total of 87 patients with GBS were reported between 2020 and 2023, of whom 75.9% were men and the average age of the patients was 43.62 ± 20.85 years. The most common variants included AIDP (56.3%) and AMAN (24.1%). Overall, 21.8% of patients had a history of COVID-19 infection in the past month and 19.5% had positive COVID-19 PCR test. There was no significant association between the distributions of disease variants with other variables except year. The incidence rate of GBS in the population covered by Kerman University of Medical Sciences was estimated to be 1.33 cases per 100,000 person-year.
conclusionOur study suggests that the overall incidence rate and clinical outcomes of GBS remained relatively consistent with pre-pandemic levels. Further research is needed to elucidate the complex relationship between GBS, COVID-19, and vaccination and to explore potential risk factors for severe outcomes in GBS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.